The panel took an historical look at the understanding of FH, presented strategies for early identifi
cation and cascade screening, explained advanced approaches to optimizing outcomes in severe FH and Homozygous FH, including LDL Apheresis and the new therapies available for the treatment of Homozygous FH: lomitapide and mipomersen. It was a wonderful opportunity to focus on FH, including developments for people with HoFH, and raise awareness among CMHC attendees. Many thanks to the organizers, sponsors, and all who came!!